Redlight Guide

Rheumatoid arthritis

Red light therapy for rheumatoid arthritis

Evidence from Cochrane and newer meta-analyses on low-level laser therapy in rheumatoid arthritis.

Study count

Cited source set includes 3 records, including 1 source(s) imported from the PlatinumLED news source inventory.

Evidence grade

low

Panel relevance

partially-replicable

Bottom line

Rheumatoid arthritis should be a medical-caveat category with weak/mixed evidence.

Consensus: Older reviews suggested short-term symptom relief, but newer evidence is more cautious and does not support strong efficacy claims.

What the studies found

  • An older Cochrane review found short-term pain and morning-stiffness reductions.
  • A 2023 review found low-quality evidence suggesting infrared laser may not be superior to sham for multiple outcomes.
  • Evidence for red laser and laser acupuncture remains very uncertain.
  • Platinum-sourced additions broaden the citation map; imported records need full-text review before converting them into stronger efficacy claims.

Dosage and timing

WavelengthsNot settled nm
IrradianceNot settled
FluenceNot settled
Session timeVaried across trials.
FrequencyVaried across trials.
DurationVaried across trials.
TimingNo time-of-day consensus.
Treatment areaAffected joints or trial-specific targets.
Device typesClinical low-level laser therapy.
NotesNewer review found infrared laser may not differ from sham.
  • No reliable consumer protocol.
  • Dose, wavelength, and application site effects remain insufficiently resolved.
  • Do not imply immune-disease treatment.
  • Imported records with missing protocol fields are not used as calculator presets.

Caveats

  • Rheumatoid arthritis requires medical care and disease-modifying treatment decisions.
  • Avoid replacing medication or rheumatology guidance with light therapy claims.
  • Some added citations are indirect, mechanistic, animal, or specialist-device studies and should not be generalized to home panels.

Cited peer-reviewed sources

meta-analysis 18 included studies Evidence: low; direction: no-clear-effect Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Varied by trial / Varied by trial Area: Affected joints or acupuncture/reflexology targets depending on trial Device: Low-level laser therapy Source

Lourinho I, Sousa T, Jardim R, et al. PLOS One. 2023.

A 2023 review found low-quality evidence suggesting infrared laser may not differ from sham in adults with rheumatoid arthritis.

Source

systematic-review 5 included studies Evidence: low; direction: mixed Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Varied by trial / Short-term trials Area: Joints or other trial-specific application sites Device: Low-level laser therapy Source

Brosseau L, Robinson V, Wells G, et al. Cochrane Database of Systematic Reviews. 2005.

An older Cochrane review found short-term pain and morning-stiffness improvements but insufficient data on key dosing factors.

Source

other Study count not extracted Evidence: very-low; direction: mixed Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Not extracted from Platinum intake metadata / Not extracted from Platinum intake metadata Area: Not extracted Device: Peer-reviewed source; device/protocol requires full-text review Source

Zhang R, Qu J. Int J Mol Sci. 2023.

Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.

Source

Last reviewed: 2026-06-15